Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Insight Molecular Diagnostics (IMDX) Invested Capital (2020 - 2025)

Insight Molecular Diagnostics' Invested Capital history spans 6 years, with the latest figure at -$8.1 million for Q3 2025.

  • For Q3 2025, Invested Capital fell 176.0% year-over-year to -$8.1 million; the TTM value through Sep 2025 reached -$8.1 million, down 176.0%, while the annual FY2024 figure was -$12.0 million, 152.88% down from the prior year.
  • Invested Capital for Q3 2025 was -$8.1 million at Insight Molecular Diagnostics, down from $1.8 million in the prior quarter.
  • Across five years, Invested Capital topped out at $109.2 million in Q1 2021 and bottomed at -$12.0 million in Q4 2024.
  • The 5-year median for Invested Capital is $36.3 million (2023), against an average of $42.7 million.
  • The largest annual shift saw Invested Capital soared 186.47% in 2021 before it crashed 176.0% in 2025.
  • A 5-year view of Invested Capital shows it stood at $66.5 million in 2021, then plummeted by 48.28% to $34.4 million in 2022, then tumbled by 33.79% to $22.8 million in 2023, then plummeted by 152.88% to -$12.0 million in 2024, then surged by 32.43% to -$8.1 million in 2025.
  • Per Business Quant, the three most recent readings for IMDX's Invested Capital are -$8.1 million (Q3 2025), $1.8 million (Q2 2025), and $10.7 million (Q1 2025).